Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial›Equity, diversity and inclusion

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial · Equity, diversity and inclusion

Equity, diversity and inclusion

CC BY 4.0 · National Institute for Health and Care Research · approximately 2 min read

The MePFAC study enrolled 162 men and women, with advanced cancer from 17 palliative care services across England, including hospital support teams, palliative care outpatient clinics, community palliative care services and hospices. Our study sample was reasonably balanced with regard to the sexes, with 86/159 (54%) of the sample being women. According to Cancer Research UK statistics,41 adults aged 50–74 account for more than half (54%) of all new cancer cases, and the four most common cancers are breast, prostate, lung and bowel. The mean age of participants in the MePFAC trial was 63.7 years, and the four most common cancers in our study population mirrored the frequency of these diagnoses in the general population. In keeping with what one would expect of a palliative care population, 41% of our study sample were on strong opioids and 78% had either recently received, were currently receiving or were scheduled to start palliative disease-modifying therapies at the time of study enrolment.

In an effort to keep data collection to a minimum, we did not collect data about the ethnicity of participants in the trial. The rationale for this was that we wished to only collect the minimum number of data to reduce participant burden. Indeed, in the first version of the protocol, to minimise data collection procedures, we did not even collect detailed diagnostic data about patients’ cancer diagnoses (we only recorded whether or not they fulfilled the study inclusion and exclusion criteria – advanced incurable cancer receiving palliative care). Moreover, we had no prior hypothesis (and there were no previous studies to suggest) that ethnicity would be a modifier of treatment response. However, in retrospect, the failure to collect ethnicity data was a limitation and has not allowed us to make any statements about the representativeness of included participants with regard to ethnic diversity.

The gender balance, age distribution, diagnostic spread, use of concomitant medication and wide geographical diversity of our recruitment strategy suggest that our findings are likely to be generalisable.

← Patient and public involvementImpact and learning →

Attribution. Patrick Stone; Ollie Minton; Alison Richardson; Peter Buckle; Zinat E Enayat; Louise Marston et al. (2025). Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial. National Institute for Health and Care Research. Copyright © 2025 Stone et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK616759. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • Equity, diversity and inclusion

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support